Showing 5811-5820 of 9416 results for "".
- Calling all Innovators: J & J Launches Digital Beauty QuickFire Challengehttps://practicaldermatology.com/news/calling-all-innovators-j-j-launches-digital-beauty-quickfire-challenge/2457975/Johnson & Johnson Innovation LLC, in collaboration with Johnson & Johnson Consumer Inc., is launching the Digital Beauty QuickFire Challenge. The challenge will encourage start-up companies to create the most novel, future-forward digital
- ADAM Now Accepting Nominations for 2018 Practice Manager of the Year Awardhttps://practicaldermatology.com/news/adam-now-accepting-nominations-for-2018-practice-manager-of-the-year-award/2457976/The Association of Dermatology Administrators and Managers (ADAM) is now accepting nominations for its annual Practice Manager of the Year Award, made possible in collaboration with CareCredit. Now in its fifth year, the Practice Manager of the Year Award identifie
- Possible Eczema Breakthrough? S. aureus May Promote Skin Inflammation via IL-36-Mediated T Cell Responseshttps://practicaldermatology.com/news/possible-eczema-breakthrough-s-aureus-may-promotes-skin-inflammation-via-il-36-mediated-t-cell-responses/2457978/Toxin-producing bacteria on the surface of our skin may induce a protein that causes our own cells to react and cause inflammation, according to research published online in Cell Host & Microbe. <
- Novan Plans to Complete Development of SB204 Acne Candidate via Third Party Funding and Executionhttps://practicaldermatology.com/news/novan-plans-to-complete-development-of-sb204-acne-candidate-via-third-party-funding-and-execution/2457981/Novan, Inc., has agreed in principle to a business structure that would enable further development and advancement of SB204 for the treatment of acne vulgaris via third party financing and third party execution of one additional Phase 3 pivotal trial that is required before the filing of a New Dr
- Save the Dates: eRelevance Launches National Marketing Education Tour for Aesthetic Healthcare Practiceshttps://practicaldermatology.com/news/erelevance-launches-national-marketing-education-tour-for-aesthetic-healthcare-practices/2457983/eRelevance Corporation announced the expansion of its popular marketing education workshops to more cities nationwide. The workshops help aesthetic healthcare providers understand the significant opportunity in marketing to their existing patient
- FDA Accepts Ortho Dermatologic's NDA for Novel Plaque Psoriasis Treatment, IDP-118https://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-nda-for-novel-plaque-psoriasis-treatment-idp-118/2457988/The US Food and Drug Administration has accepted Ortho Dermatologic's New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date i
- Use of a New Holographic Hand Piece May Improve Picosecond Laser Treatment of Acne Scarshttps://practicaldermatology.com/news/study-adding-a-holographic-beam-splitter-to-picosecond-laser-improves-acne-scars/2457993/Incorporating a new holographic beam splitter in a picosecond laser may help improve the appearance of acne scars, according to a study published in Lasers in Surgery and Medicine (LSM). The paper was selecte
- Chris Greta Appointed Chief Creative Officer at eRelevancehttps://practicaldermatology.com/news/chris-greta-appointed-chief-creative-officer-at-erelevance/2457996/Chris Greta has been appointed as the first chief creative officer for
- Prospective Cosmetic Surgery Patients Often In The Dark About Financing Optionshttps://practicaldermatology.com/news/prospective-cosmetic-surgery-patients-in-the-dark-about-financing-options/2457994/Fully 76 percent of prospective patients are unaware of financing options for cosmetic procedures, yet almost two-thirds of them would be more likely to book if they were aware that financing was a viable option, according to a survey by
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF